Comparative Pharmacology
Head-to-head clinical analysis: DILAUDID versus PALLADONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILAUDID versus PALLADONE.
DILAUDID vs PALLADONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dilaudid (hydromorphone) is a full opioid agonist with high affinity for mu-opioid receptors, producing analgesia by mimicking endogenous endorphins and enkephalins. It also activates kappa and delta opioid receptors to a lesser extent.
Agonist at mu-opioid receptors, modulating pain perception via central and peripheral pathways.
Initial: 2-4 mg orally every 4-6 hours as needed; or 1-2 mg intramuscularly, subcutaneously, or intravenously every 4-6 hours as needed.
Immediate-release: 4-8 mg orally every 4-6 hours as needed for pain; extended-release: 8 mg orally every 12 hours, titrated based on response and tolerance.
None Documented
None Documented
2.5-3.5 hours (terminal); prolonged in hepatic/renal impairment
Terminal elimination half-life is approximately 18 hours (range 12-24 h); supports extended dosing intervals.
Primarily renal (90% as hydromorphone-3-glucuronide and parent drug); <1% biliary/fecal
Primarily renal (90%) as unchanged drug and glucuronide conjugate; ~10% biliary/fecal.
Category C
Category C
Opioid Analgesic
Opioid Analgesic